The study authors conclude that patients with B-cell non-Hodgkin lymphoma hospitalized for Covid-19 have a high incidence of prolonged evolution of SARS-CoV-2 infection. Administration of anti-CD20 therapy within the last 12 months is one of the main risk factors for longer in-hospital stay and death of Covid-19. The study shows that the risk of persistent Covid-19 was also higher in patients older than 70 years or with refractory or relapsed disease. These findings may contribute to guiding the management of lymphoma patients during the Covid-19 pandemic.

The study authors conclude that this first analysis from DESCAR-T registry seems to confirm CAR-T cells efficacy in real life and be in line with previously published data. Updated results are presented at the meeting.  

The study authors conclude that their findings confirm the existence of molecular subtypes of R&R DLBCL, providing evidence that the curative effect of CAR T cells immunotherapy differs in diverse subtypes. CAR T cells immunotherapy can prolong survival times in some subtypes thought previously associated with worse outcomes. We provide potential precision-medicine strategies for R&R DLBCL patients with poor prognoses.

The study authors conclude that these results demonstrate that valemetostat has an acceptable safety profile in patients with R/R NHLs and encouraging efficacy results in patients with R/R PTCL or R/R ATL and warrants further evaluation.